Bryan Garnier & Cie upgraded the shares of UBSFY in report on Thursday, October 15 to "Buy" rating. Including today's unusual volume, Mirati Therapeutics, Inc.'s stock is performing at 135.79% on the year. (NASDAQ:MRTX) for 399,317 shares. About 12.93 million shares traded or 9716.43% up from the average.
Covering sell-side analysts have recently weighed in on shares of Mirati Therapeutics, Inc. It has underperformed by 93.21% the S&P500. It was reported on Sep, 16 by Barchart.com. We have $10.28 PT which if reached, will make NASDAQ:MRTX worth $7.12 million more.
Based on the latest notes released to investors, 1 analyst has issued a rating of "buy", 2 analysts "outperform", 2 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Therefore 63% are positive. Jefferies Group LLC reiterated a "hold" rating and issued a $4.50 price target on shares of Mirati Therapeutics in a report on Monday, June 12th. The rating was downgraded by Piper Jaffray to "Neutral" on Thursday, September 17. H.C. Wainwright initiated the shares of MRTX in report on Thursday, November 17 with "Buy" rating. The rating was maintained by Jefferies on Friday, August 4 with "Hold". (NASDAQ:MRTX) earned "Hold" rating by Jefferies on Monday, June 12.
03/01/2016 - SunTrust began new coverage on Mirati Therapeutics, Inc. giving the company a "buy" rating. (NASDAQ:MRTX). Jpmorgan Chase & has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, June 6 to "Mkt Perform" rating.
06/06/2016 - Mirati Therapeutics, Inc. had its "buy" rating reiterated by analysts at Citigroup. Mirati Therapeutics has a 1-year low of $4.40 and a 1-year high of $24.86. (NASDAQ:MRTX) has "Overweight" rating given on Monday, October 19 by Barclays Capital.
Investors sentiment decreased to 0.68 in Q4 2016. Its down 0.20, from 1.02 in 2016Q3. KCG Holdings Inc. purchased a new stake in Mirati Therapeutics in the first quarter worth about $106,000. 7 funds opened positions while 18 raised stakes.
TRADEMARK VIOLATION NOTICE: "Mirati Therapeutics, Inc". (NASDAQ:MRTX). Ghost Tree Capital Lc has invested 0.2% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Morgan Stanley owns 69,101 shares for 0% of their portfolio. Sabby Mgmt Llc holds 99,735 shares. 48,767,398 shares of the company's stock were exchanged. (NASDAQ:MRTX) for 22,826 shares. Bnp Paribas Arbitrage reported 758 shares stake. Jefferies maintained Mirati Therapeutics, Inc. 523,812 are owned by Vanguard Group Incorporated Incorporated. Susquehanna International Group LLP grew its position in shares of Mirati Therapeutics by 46.5% in the 2nd quarter. (NASDAQ:MRTX). Venbio Select Advisor Limited Liability Corporation reported 1.51M shares. North Amer Management owns 9,835 shares for 0.11% of their portfolio. Blackrock Mngmt Ltd Liability owns 43,605 shares.
Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Friday, May 6 to "Market Outperform" rating. They expect $-0.85 EPS, up 12.37% or $0.12 from last year's $-0.97 per share. After $-0.74 actual earnings per share reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 14.86% negative EPS growth.